Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buprenorphine + combined hormonal contraceptive
- Development stage
- Unknown
- Lead developer
- Indivior
- Modality
- Small Molecules
- Administration
- Oral, Transdermal, Vaginal, Sublingual, Buccal, Subcutaneous, Intravenous, Intramuscular
01
Overview
This entry refers to the co-administration of two distinct pharmaceutical agents—buprenorphine and a combined hormonal contraceptive (CHC). Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor, primarily used for opioid use disorder (OUD) and pain management. It reduces cravings and withdrawal symptoms in opioid-dependent individuals while having a ceiling effect that lowers overdose risk compared to full agonists[5][6][9]. Combined hormonal contraceptives are medications containing both estrogen and progestin, used for birth control by inhibiting ovulation, altering cervical mucus, and changing endometrial lining. There is no single fixed-dose combination product of these two agents; rather, this term describes their concurrent use in clinical practice.
- Other names
- buprenorphine + CHCbuprenorphine plus combined hormonal contraceptive
02
Targets
KOR (Kappa opioid receptor)PR (Progesterone receptor)MOR (Mu opioid receptor)ER (Estrogen receptor)
Beyond the preview
Go deeper on buprenorphine + combined hormonal contraceptive.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buprenorphine + combined hormonal contraceptive.